Sanofi-a Ventis Deutschland Gmbh

UniversitÄt Zu Koln

Andreas R Klatt

Eckart Bartnik

Joerg Czech

Ekkehard Leberer

Thomas Leeuw

Sebastian Barradeau

Matthias Schneider

Benedikt Ostendorf

Georg Pongratz

Gabriele Hermes

Johannes Ruthard

Methods, kits, and active ingredients for diagnosing or treating arthritis or a degenerative disease of the skeletal system, or for selection of subjects for therapy. The methods for diagnosing arthritis involve the detection of an autoantibody, which is associated with arthritis, or excluding the presence of an autoantibody against collagen II. The methods for diagnosing a degenerative disease of the skeletal system, involve the detection of an autoantibody against thrombospondin-4 or COMP. The kits contain a detection agent for an autoantibody and can be used for diagnosing arthritis or a degenerative disease of the skeletal system. The active ingredient can be used for treating or preventing autoimmune-associated arthritis.

Detection of autoantibodies for diagnosing degenerative diseases of the skeletal system

The invention refers to the use of a p21-activated kinase (PAK) inhibitor as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.

Use of PAK inhibitor for the treatment of a joint disease

The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.

Growing community of inventors

Cologne, Germany

Andreas R Klatt